|
|
EN
  • 業務谘詢

    中國:

    Email: marketing@yakkaa.com

    業務谘詢專線:400-780-8018

    (僅限服務谘詢,其他事宜請撥打川沙總部電話)

    川沙總部電話: +86 (21) 5859-1500

    海外:

    +1(626)986-9880(U.S. - West Coast)

    0044 7790 816 954 (Europe)

    Email:marketing@medicilon.com

在線留言×
點擊切換
News information
新聞資訊

KRAS的信號通路

2023-12-19
|
訪問量:

KRAS信號的激活是一個多步驟的過程,需要適當的KRAS翻譯後修飾,細胞膜定位與效應蛋白的相互作用。

The activation of KRAS signaling is a multi-step process that requires proper KRAS post-translation,plasma membrane-localization and interaction with effector proteins.

在細胞外刺激作用下,從失活的RAS-GDP到激活的RAS-GDP的轉化進一步促進了多種信號通路的激活,包括MAPK通路、PI3k 通路和Ral-GEFs通路,其中以MAPK通路的特征最為明顯。

In response to extracellular stimuli, the conversion from inactive RAS-GDP to active RAS-GDP further promotes the activation of various signaling pathways, which includes MAPK pathway,PI3k pathway and the Ral-GEFs pathway,among them the MAPK pathway is the best characterized.

RAS-GDP直接與RAF蛋白結合,將RAF激酶家族從細胞質招募到膜上,在細胞膜上二聚化並活化。激活的RAF隨後對其下遊底物,即MEK and ERk進行一係列磷酸化反應,並傳導生長信號。

RAS-GDP directly binds to RAF protein,recruiting RAF Kinese family from cytoplasm to membranes,where they dimerize and become active. The activated RAF subsequently carries out a chain of phospholation reactions to its downstream substrates, MEK and ERk, and propagates the growth signal.

更多“KRAS靶點”相關內容推薦

KRAS新藥研發平台

什麽是KRAS?

hjc黄金城助力信諾維抗腫瘤1類新藥XNW14010(小分子KRAS G12C蛋白共價結合抑製劑)獲批臨床

相關新聞